VidPrevtyn Beta


COVID-19 Vaccine (recombinant, adjuvanted)

This medicine is authorised for use in the European Union.


VidPrevtyn Beta is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 18 years and older. It can be used once as a booster in people who have already received an mRNA or adenoviral vector COVID-19 vaccine.

VidPrevtyn Beta contains a version of a protein found on the surface of SARS-CoV-2 (the spike protein of the virus that causes COVID-19), which has been produced in the laboratory.

This EPAR was last updated on 30/11/2022

Authorisation details

Product details
VidPrevtyn Beta
Agency product number
Active substance
SARS-CoV-2 prefusion Spike delta TM protein, recombinant (B.1.351 strain)
International non-proprietary name (INN) or common name
COVID-19 Vaccine (recombinant, adjuvanted)
Therapeutic area (MeSH)
COVID-19 virus infection
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Sanofi Pasteur
Date of issue of marketing authorisation valid throughout the European Union
Contact address

14 Espace Henry Vallée
69007 Lyon

Product information

10/11/2022 VidPrevtyn Beta - EMEA/H/C/005754 -

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

VidPrevtyn Beta is indicated as a booster for active immunisation to prevent COVID-19 in adults who have previously received an mRNA or adenoviral vector COVID-19 vaccine (see sections 4.2 and 5.1 in product information document).

The use of this vaccine should be in accordance with official recommendations.

Assessment history

How useful was this page?

Add your rating
2 ratings
1 rating